Cipla India Plant Receives FDA-483
India-based Cipla Ltd. has been issued a two-item Form FDA-483 after a 6/27-7/1 FDA inspection at its Madhya Pradesh, India manufacturing plant. According to the inspection form, the firm was cited for:
- Equipment and utensils not being cleaned and maintained at appropriate intervals to prevent
- Drug product samples for determining conformance to written specifications are not being properly identified.